



## argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022

April 28, 2022

**Breda, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 5, 2022 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2022 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at [argenx.com/investors](http://argenx.com/investors). A replay of the webcast will be available on the argenx website for approximately one year following the call.

### Dial-in numbers:

*Use the access code 073235 to join the call. Please dial in 15 minutes prior to the live call.*

Belgium	32 800 548 13
United Kingdom	44 808 189 6484
United States	1 844 200 6205
All other locations	1 929 526 1599

### About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit [www.argenx.com](http://www.argenx.com) and follow us on [LinkedIn](#), [Twitter](#), and [Instagram](#).

### For further information, please contact:

#### Media:

Kelsey Kirk  
kkirk@argenx.com

#### Investors:

Beth DelGiacco  
bdelgiacco@argenx.com

Michelle Greenblatt  
mgreenblatt@argenx.com